People · Operator
Named in public records as an officer, director or promoter · active 2013–2019 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Semma Therapeutics, Inc. | — | Biotechnology | Series D+ | $129.3M | $4.7B | 2015 |
| CoStim Pharmaceuticals Inc. | — | Pharmaceuticals | Series A | $10.0M | $309.9M | 2013 |
| Nayan Therapeutics, Inc. | — | Biotechnology | Seed | $3.0M | $133.2M | 2019 |
Robert Millman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert Millman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jean-Francois Formela | 1 | 17 |
| Joshua Resnick | 1 | 12 |
| Todd Foley | 1 | 12 |
| Luke Evnin | 1 | 12 |
| Josh Resnick | 1 | 7 |
| David Neafus | 1 | 7 |
| STEPHEN KNIGHT | 1 | 6 |
| Roger Kitterman | 1 | 5 |
| Kevin Raidy | 1 | 4 |
| Kazumi Shiosaki | 1 | 4 |
| Marian Nakada | 1 | 4 |
| Milind Deshpande | 1 | 4 |
| Mitchell Finer | 1 | 3 |
| MARK FISHMAN | 1 | 3 |
| Daniel Auerbach | 1 | 3 |
| Bastiano Sanna | 1 | 2 |
| Jim Scopa | 1 | 2 |
| Mitch Finer | 1 | 2 |
| William Sahlman | 1 | 2 |
| Elizabeth Stoner | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.